Methotrexate-d3

Methotrexate-d3 is intended for use as an internal standard for the quantification of MTX (Cay-13960) by GC- or LC-MS. MTX is similar in structure to folic acid (Cay-20515) and aminopterin (Cay-21802). It acts by inhibiting the metabolism of folic acid and blocking key enzymes in the synthesis of purines and pyrimidines required for cell proliferation. MTX is known to induce adenosine release, which mediates many of its anti-inflammatory effects, including the reduction of proinflammatory cytokines. Formulations containing MTX have been used in the treatment of cancer, autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. MTX formulations are considered the gold standard of disease-modifying antirheumatic drug (DMARD) therapy to treat both the immune-inflammatory and joint destructive processes of rheumatoid arthritis.Formal Name: N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methyl-d3-amino]benzoyl]-L-glutamic acid. CAS Number: 432545-63-6. Synonyms: Amethopterin-d3, MTX-d3. Molecular Formula: C20H19D3N8O5. Formula Weight: 457.5. Purity: >99% deuterated forms (d1-d3). Formulation: (Request formulation change), A solid. Solubility: DMF: 14 mg/ml, DMSO: 3 mg/ml, PBS (pH 7.2): 1 mg/ml. SMILES: NC1=NC(N)=C2C(N=CC(CN(C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3)C([2H])([2H])[2H])=N2)=N1. InChi Code: InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1/i1D3. InChi Key: FBOZXECLQNJBKD-FUPFOCIHSA-N.